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Abstract 
Development of the next generations of cancer therapy modalities is currently a crucial 
requirement of oncology. Advances in nanotechnology are bringing us closer to the 
development of dual and multifunctional nanoparticles that are challenging the 
traditional distinction between diagnostic and treatment agents. The chase of 
innovative, multifunctional, more efficient, and safer treatments is a major challenge in 
preclinical nanoparticle-mediated thermotherapeutic research for breast cancer. Here, 
we report that iron oxide nanoparticles have the dual capacity to act as both magnetic 
and drug delivery agents.  
The aim of this work was to investigate the in vitro effect of the loading of doxorubicin 
(DOX) on negatively charged polycarboxylic iron-oxide nanoparticles (SPIONs) and 
Rhodamine B functionalized SPIONs on breast carcinoma cell lines. For proper 
analysis and understanding of cell behavior after administration of DOX-SPIONs 
compared with free DOX, a complex set of in vitro tests, including production of MTT 
assay, cell cycle determination, and cellular uptake, were utilized. In summary, we 
have developed a magnetic nanoparticle-based drug delivery system that sequentially 
delivers the cytotoxic drug doxorubicin to breast cancer cells (MCF-7 and MDA-MB-
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231). The drug-coated nanoparticles, DOX-NPs, were assembled stepwise, with 
doxorubicin adsorbed to bare iron oxide nanoparticles first, by electrostatic reaction 
and allowed for the complexation of doxorubicin. DOX-NPs were stable in solution at 
37 °C and physiological pH (7.4). Rapid in vitro release of doxorubicin followed by 
gradual release of doxorubicin was triggered in aqueous solution by low pH (5.4) and 
heating. As a result of minimal internalization, the particles were not significantly toxic 
to noncancerous cells (MCF-10A). In contrast, they were internalized to a much greater 
extent in MCF-7 and MDA-MB-231 cells and were cytotoxic due to the synergistic 
action of the two drugs and the effects of hyperthermia. The drug-coated particles were 
able to inhibit growth and proliferation of breast cancer cells in vitro, indicating that the 
system has potential to act as an antimetastatic chemothermotherapeutic agent. 
 
 
Introduction 
 
Breast cancer is still one of the leading causes of cancer-related deaths in women in 
Europe and worldwide [1]. Due to the implementation of improved early diagnostic 
methods, modern surgery and more effective drugs in the adjuvant setting, the average 
5-year survival rate has increased to about 90%. However, if distant metastasis occurs, 
patients are still evaluated as non-curable and have in general only a few years to live 
while on permanent drug therapy. Thus, current drug therapy is far from optimal, 
especially in the metastatic setting. Nanomedicine is a medicine made by 
nanotechnology. Drug delivery is one of the most important properties of nanomedicine. 
To increase the capacity of targeting delivery of anticancer drugs to tumors, 
nanoparticles are usually functionalized with targeted antibodies, peptides or other 
biomolecules. 
Nanomedicine is a promising therapeutic strategy for breast cancer treatment. 
Nanomedicine products such as Doxil® and Abraxane® have already been extensively 
used for breast cancer adjuvant therapy with favorable clinical outcomes. However, 
these products were originally designed for generic anticancer purpose and not 
specifically for breast cancer treatment. With better nanoengineering and 
nanotechnology action against breast cancer, a number of novel promising 
nanotherapeutic strategies and devices can be implemented. 
The growing interest in applying nanotechnology to cancer is largely attributable to its 
uniquely appealing features for drug delivery, diagnosis and imaging, synthetic vaccine 
development and miniature medical devices, as well as the therapeutic nature of some 
nanomaterials themselves [2]. The original intended use of nanomedicine is to improve 
human health. Nanosized magnetic nanoparticles are some of the best candidates for 
the development of more efficient methods for the synthesis of nanodrug delivery ve-
hicles based on iron-oxide nanoparticles. Nanotheranostics, the integration of diagnos-
tic and therapeutic function in one system using the benefits of nanotechnology, is 
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extremely attractive for personalized medicine [2]. As the conventional chemotherapy 
is administered systemically, it often causes considerable adverse reactions such as 
nausea, hair loss, and bone marrow suppression, as well as liver and kidney toxicity 
[3]. These aspects determine the dose of the chemotherapeutic agents and limit their 
effects on the tumor site [3].  
Many different novel cancer therapeutic strategies that have been explored in the last 
two decades, therapies that are responsive to external physical stimuli coupled with 
nanoparticles (NPs) that are capable of responding to light, magnetic fields, ultrasound, 
radio-frequency, or x-ray, have attracted substantial interest from many researchers 
across the world [17]. 
Magnetic fields (MF) are non-invasive in nature and have excellent human tissue pen-
etration. Owing to this characteristic of MF, it has been used in clinics for whole body 
MRI. In recent years, MF has been used to activate drug delivery into the tumor region 
through field dependent thermal and non-thermal effects. High frequency (>10 kHz) 
alternating magnetic fields (AMF) responsive MNPs can generate heat by utilizing dif-
ferent physical mechanisms. 
The drug doxorubicin (DOX) is an anthracycline antibiotic, and a leading chemothera-
peutic agent with cytostatic effect used in the treatment of different types of human 
cancers [3]. Although doxorubicin is currently considered to be one of the most effec-
tive agents in the treatment of breast cancer, the drug use is limited by absolute max-
imum total doses that may be given and resistance to therapy frequently occurs, too. 
The molecular mechanism of action of doxorubicin interacts is based on DNA interca-
lation and inhibition of macromolecular biosynthesis [4]. The most diffused molecular 
mechanism involved in the killing of cancer cells is related to the activation of apoptotic 
pathway [4].   
The main issue in the clinical use of doxorubicin is due to its heavy side effects on 
patients, especially for its intrinsic and cumulative dose-dependent cardiotoxicity [5-7]. 
To limit these side effects, doxorubicin can be encapsulated with drug nanocarriers 
that will allow targeted accumulation only on the cancer site and hence limit its disper-
sion into healthy tissues [8]. Superparamagnetic iron oxide nanoparticles (SPIONs), 
especially Fe3O4 nanoparticles, have been widely used in the field of biotechnology 
because of biocompatible, potentially non-cytotoxic, small size and interesting super-
paramagnetism properties [9]. Additionally, spherical magnetite NPs with diameters 
less than approximately 20 nm will exhibit superparamagnetic behavior, a property that 
is exploited to enhance contrast in magnetic resonance imaging (MRI) [9]. Multifunc-
tional superparamagnetic iron oxide nanoparticles (SPIONs) for cancer theranostics 
can integrate chemotherapeutics, gene therapeutics, photothermal/photodynamic 
therapeutics, magnetic hyperthermia, fluorescent moieties and targeting moieties can 
be incorporated in the polymer coating through different strategies [8] (Figure 1). 
Exploiting the interesting properties of the magnetic nanoparticles, the Fe3O4 nanopar-
ticles were modified with polycarboxylic acid and loaded with the anticancer drug dox-
orubicin (DOX) for achieving a biocompatible, biodegradable and site-specific release 
of doxorubicin in the specific cancer site. Many types of tumors have a leaky neovas-
culature characterized by incomplete endothelial barrier and they possess poor 
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lymphatic drainage. This effect, known as enhanced permeability and retention (EPR), 
allows nanosized carriers to easily reach their target site [10]. This study investigated 
both in vitro effect of induced magnetic field hyperthermia and targeted drug delivery 
of doxorubicin mediated by SPIONs on in vitro model of breast cancer. The novel dual 
targeted nanoparticles loaded with doxorubicin (DOX) and magnetic nanoparticles 
(SPIONs) can be considered a novel therapeutic tool to create personalized treatment 
in breast cancer patients. Great efforts have been made to develop drug carriers with 
the aim of providing predictable therapeutic response. Moreover, combination thera-
pies have become promising strategies for clinical cancer treatment with synergistic 
effects.    
The present study purposed to develop a new type of superparamagnetic nanocarrier 
for the intracellular co-delivery of doxorubicin (DOX) to the breast cancer cell line. A 
novel paramagnetic nanocomposite was designed to combine Rhodamine B and pol-
ycarboxylic SPIONs with doxorubicin to enhance anticancer activity. 
Keeping in mind the novel properties of the magnetic nanoparticles, the Fe3O4 nano-
particles were modified with polycarboxylic acid and Rhodamine B and loaded with the 
anticancer drug doxorubicin (DOX) for achieving a biocompatible, biodegradable and 
site-specific carrier of anticancer drugs. The effect of these drug loaded nanocom-
pounds was also evaluated on biochemical and morphological parameters of the hu-
man breast cancer cell lines of MCF-7 and MDA-MB-231. The in vitro cytocompatibility 
of the conjugate SPIONs-DOX and iron oxide nanoparticle-mediated hyperthermia was 
also evaluated on human mammary epithelial cell line (MCF-10A). 
 
Figure 1. Various approaches explored to target breast cancer using nanomedicines. 
 
Breast cancer nanotheranostics 
The next generation cancer nanomedicine theranostics approach used for 
interventional oncology allows the diagnosis and treatment of cancer using targeted 
minimally invasive procedures performed under image guidance [18]. The current use 
of iron-oxide nanoparticles in breast cancer falls into four main groups: (1) imaging of 
primary and metastatic disease, (2) sentinel lymph node biopsy (SLNB), (3) drug 
delivery systems, and (4) magnetic hyperthermia [18]. The current evidence for the use 
of MNPs in these fields is mounting, and potential cutting-edge clinical applications, 
particularly with relevance to the fields of breast oncological surgery, are emerging [19]. 
Radiation therapy is a mainstay of treatment for patients with high grade gliomas, 
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including glioblastoma. Radiation therapy in conjunction with surgery has been shown 
to prolong survival and, in the short term, improve cognitive function in patients with 
brain tumors. Over the longer term, however, radiation can cause fatigue and serious, 
permanent side effects, including radiation necrosis. Proton beam therapy, on the other 
hand, delivers very precise, very high doses of radiation to a tumor site, while sparing 
the surrounding healthy tissue [18, 19]. 
 
Materials and methods 
 
Synthesis of n(COOH) SPIONs 
 
SPIONs were synthesized via the co-precipitation method. Initially, FeSO4·7H2O and 
FeCl3 (Sigma-Aldrich) were dissolved in water in 1:2 M ratios under nitrogen protection. 
The resulting dark orange solution was stirred for 30 min at 80 °C. An aqueous NH3 
solution (1.5 M) was then added dropwise to the above hot solution with stirring over a 
period of 15 min. Instant color change from dark orange to black was found to occur 
with particle formation. Stirring was continued for further 30 min followed by cooling to 
room temperature. Then 4 mL of an aqueous solution of citric acid (0.5 g/mL) was 
added to the above reaction mixture and reaction temperature was slowly raised up to 
90 °C under reflux and reacted for 60 min with continuous stirring. The solvent was 
removed by magnetic decantation. Washing of the particles was done several times 
with water and then ethanol to make the iron dispersion free of any residual salts, which 
was used during the coprecipitation. The final supernatant was decanted magnetically 
to obtain the as-prepared superparamagnetic Fe3O4-(COOH)n NPs. 
 
Surface coating of SPIONs with Rhodamine-B 
 
About 2 mg RhB was dissolve into 2 mL DMSO : H2O (1 : 1), then, a solution of EDC 
(8.7 mg, 10 mmol) and NHS (5.2 mg, 10 mmol) in MES buffer (2 mL) was added and 
incubated for 3 min. The obtained product was preserved in refrigerator at 4 °C. After-
wards 12 mg of the iron-oxide nanoparticles were introduced into 25 mL deionized 
water. After a brief sonication, solution of 5 mg of copper sulfate in 0.5 mL of water and 
22 mg of sodium ascorbate in 1.0 mL of water were added, and the mixture was stirred 
for 30 min, then mixed with RhB and stirred in the room temperature all night. The final 
product was recovered by centrifugation and washed with PBS (pH = 7.0). 
 
 
 
Physicochemical Characterization of iron-oxide nanoparticles 
 
The morphology and size distribution of SPIONs were studied by transmission electron 
microscopy (TEM) and the hydrodynamic size and surface potential were measured 
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through dynamic light scattering (DLS) and zeta potential, respectively. Furthermore, 
the crystalline phase of SPIONs was confirmed by X-ray diffraction (XRD, λ = 0.15406 
nm) and was detected by Fourier-transform infrared spectroscopy (FTIR). Cell inter-
nalization of SPIONs was assessed inside the MCF7 cells by ICP-MS after 2 h incu-
bation with SPIONs.  
 
 
Experiment 
  
X-Ray powder diffraction (XRD) measurements were performed on a powder sample 
of the Fe3O4 nanoparticles using a Rigaku D/Ultima IV X-ray diffractometer (Rigaku, 
JAPAN), which was operated at 35 kV and 40 mA at a scan rate of 0.4 deg s-1 and 2θ 
ranges from 10° to 90° at room temperature using Cu-Ka radiation (λ = 0.1542 nm). 
Transmission electron microscope (TEM) images were obtained at 200 kV by a JEM 
2010 (JEOL, JAPAN) instrument. A drop of suspension of magnetite in ethanol (20 mg 
mL-1) before and after modification was placed on a carbon-coated copper grid (Xinxin 
Bairui Corp, Beijing, China) and air dried. Fourier transform infrared (FTIR) spectra 
were recorded on a NEXLIS FTIR (Nicolet Corporation) and samples were dried at 90 
C vacuum for at least 3 h prior to fabrication of the KBr pellet. In this context 4 mg of 
each sample was thoroughly mixed and crushed with 400 mg of KBr, and 70 mg of that 
mixture was used for pellet fabrication. Thirty-two scans of the region between 400 and 
4000 cm-1 were collected for each FTIR spectrum recorded.  
 
 
 
 
Dynamic light scattering (DLS) measurement of particle size distribution 
DLS was applied to measure size distribution of released DOX-SPIONs. Briefly, DOX-
SPIONs nanoparticles were suspended in 200 μl of PBS (pH 7.4 or 6.6), followed by 
shaking at 300 rpm in a thermomixer (Eppendorf, Germany) at 37°C for 12 h. 
Supernatants containing released DOX-SPIONs nanoparticles were collected by 
centrifugation at 2,000 rpm for 4 min. SPIONs controls were prepared by the same 
procedure. DOX-SPIONs controls were prepared by direct dispersion of 5 μl DOX DMF 
solution into 2 mL PBS (pH 7.4 or 6.6). Particle size was measured with a Zetasizer 
Nano-ZS (Malvern Instruments Ltd, Worcestershire, UK) with measurements made 
using intensity average. 
 
Stability of SPIONs 
 
The stability of SPIONs was investigated by recording the change in turbidity in 50% 
FBS. 150 μl of SPIONs suspension (100 μg/ml) was added to 150 μl of FBS in 96-well 
plates and incubated for different times up to 72 h at 37 °C. After that, the absorbance 
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of samples was measured at 405 nm. A solution of 5% glucose was employed as a 
negative control [9]. 
 
Conjugation of DOX to the SPIONs 
 
For drug conjugation to modified SPIONs, different concentrations (50 and 100 µg/ml) 
of negatively charged polycarboxylic iron-oxide nanoparticles SPIONs were first soni-
cated with 0.5, 1, 5 and 50 µM concentrations of doxorubicin (DOX – Sigma-Aldrich) 
solution for 0.5 h and then stirred overnight at room temperature in the dark. DOX 
loading of modified SPIONs at an initial drug concentration of 50 µM was nearly satu-
rating. The conjugation of doxorubicin to Rhodamine-B SPIONs was done by mixing 
0.5, 1, 5 and 50 µM concentrations of doxorubicin (DOX) to 50 µg/ml RhB-SPIONs and 
then separating the DOX-RhB-SPIONs from precursors. 
All the samples were centrifuged at 18 000 x g for 1 h. The DOX concentration of all 
the samples was measured using a standard DOX concentration curve, generated with 
a UV-Vis spectrophotometer (Cary 60 UV-Vis – Agilent) at the wavelength of 233 nm. 
The drug conjugation to the n(COOH)-SPIONs has been illustrated in Figure 2.  
 
 
Figure 2. Conjugation of doxorubicin (DOX) to the n(COOH)-SPIONs. 
 
Cell cultures 
The human breast cancer cell lines MCF-7 (ATCC - HTB-22) and MDA-MB-231 (ATCC 
- HTB-26) cells were obtained from the American Type Culture Collection and cultured 
in DMEM, containing 1% (v/v) penicillin-streptomycin and 10% (v/v) heat-inactivated 
FBS, respectively. FBS and penicillin-streptomycin were obtained from GIBCO - Life 
Technologies, Carlsbad, CA, USA.  
Human mammary epithelial cells (MCF 10A, ATCC, CRL-10317) was cultivated in ™ 
Mammary Epithelial Cell Growth Medium (MEGM, Lonza/Clonetics) fortified with 2 mM 
L-glutamine, 100 ng/ml cholera toxin, 10% fetal bovine serum (FBS, Gibco, Thermo-
Fisher, Pittsburg, PA, US) and 1% antibiotics/antimycotics 
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(penicillin/streptomycin/gentamycin, Gibco) (complete medium). Cells were incubated 
in a humidified 5% CO2 atmosphere at 37°C and passaged twice weekly at a 1:4-5 
concentration.  
 
Magnetic hyperthermia in breast cancer and normal cells 
 
Breast cancer cells were exposed to hyperthermia conditions to induce mediated apop-
tosis.  For hyperthermia treatment, at 24 h after seeding 5000 cells/well in a 96-well 
plate, cells were incubated with either medium, DOX-SPIONs in a concentration of 50 
μg Fe/ml or the equivalent molar amount of free DOX at 46°C for 30 minutes in contact 
with a magnet, corresponding to a temperature dosage of 90 cumulative equivalent 
minutes at 43°C, or else cells was left in the incubator at 37°C. At 48 h after hyperther-
mia, cells viability was tested. The in vitro efficacy was also tested without hyperther-
mia treatment. Immediately afterward, the viability of cells was assessed by MTT assay. 
 
 
Leaching toxicity tests of MNPs 
For leaching toxicity tests the SPIONs were sterilized with UV and MEGM culture 
medium containing 10% calf serum was then added to it in a sterile closed vessel (final 
concentration 0.1 g/mL). Leaching conditions were 37°C over 72 hours. The samples 
were then centrifuged at 2500 rpm for 5 minutes, the supernatant was removed by 
suction and filtered through a microporous filter (VWR International, U.S.) to provide a 
100% leach solution. During the test, the MEGM culture medium was diluted to the 
required concentration. MCF-10A cells were removed during their logarithmic growth 
phase and digested in the cell suspension; the cell concentration was next adjusted to 
4 × 103/mL and inoculated on a 96-well culture plate at 200 μl/well. The sample was 
cultured in an incubator at 37°C under saturated humidity and 5% CO2 conditions. The 
primary solution was discarded after 24 hours, at which time the leaching solution was 
added until the final concentration was 100%, 75%, 50%, and 25%. The MEGM culture 
inoculum was used as control. Each group comprising four wells was cultured for 72 
hours, and 20 μl of MTT was then added into each well and incubated for 4 hours. The 
absorbance value was measured at 570 nm using a spectrophotometer. The relative 
cell growth rate was calculated as follows: relative growth rate % = OD (Optical Density) 
mean value of test group/OD mean value of negative control group × 100%. 
 
Cell viability and apoptosis analyses  
 
Viability was determined by MTT assay. Data obtained were used to calculate the IC50 
and IC90 values for each cell line, administered with DOX-n(COOH)-SPIONs. For all 
experiments, 3 x 106 cells from each cell line were plated into 150 mm tissue culture 
dishes, 24 h prior to the nano-composite treatment. In order to determine the corre-
sponding IC50 and IC90 values, the cells were separately treated with the as-prepared 
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bare, coated and drug-loaded nano-composites for 24, 48, 72 and 96 h at 37 °C. Plates 
were washed thrice with PBS and incubated in 10 mL of fresh medium for an additional 
48 h before the final cell collection. All the cells were collected by sedimenting at 2000 
x g for 5 min. For the 5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide (MTT) as-
say, MCF-7 and MDA-MB-231 cells were plated in 96-well plates and exposed to 
n(COOH)-SPIONs, RhB-SPIONs and DOX-n(COOH)-SPIONs at a concentration of 50 
µg/mL for 24, 48, 72 and 96 h. After the culture period, the medium was removed from 
each well and replaced with fresh medium. Cellular apoptosis was detected by An-
nexin-V-FLUOS staining and studied with the help of flow cytometry.  
 
Direct cytotoxicity evaluation of SPIONs and DOX-SPIONs on cancer cells 
Direct cytotoxicity of SPIONs on breast cancer cells was evaluated following the ISO 
standard 10993-5:2009 on Biological Evaluation of Medical Devices instructions [3]. 
Cells were seeded in 24-well plates (1.6 x 104 cells per well) in complete DMEM 
medium and incubated for 24, 48 and 72 h at 37°C in 5% CO2. Different combinations 
of hyperthermia and targeted drug delivery of doxorubicin were tested on breast cancer 
cells to observe their efficacy. Fresh medium without MNPs was used as control. Cell 
viability was evaluated after 24, 48 and 72 hours by the (3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide colorimetric assay (MTT, Sigma). Briefly, 100 μl of 
MTT solution (3 mg/ml in PBS) were added to each specimen and incubated for 4 
hours in the dark at 37°C; formazan crystals were then dissolved in 100 μl of dimethyl 
sulphoxyhde (DMSO, Sigma- Aldrich) and 50 μl were collected and centrifuged to 
remove any debris. Supernatant optical density (o.d.) was evaluated at 570 nm. The 
mean optical densities obtained from control specimens were taken as 100% viability. 
Cell viability was calculated as follow: (experimental o.d. / mean control o.d.)*100. 
Experiments were performed with four replicates at each experimental time. 
 
Cell uptake analysis 
 
Visual determination of cell uptake and incorporation of Rhodamine B-SPIONs were 
performed using optical microscopy with fluorescent mode. For comparison with in vitro 
battery tests used in this work, we tracked the efficiency of labeling and cell morphology 
after 24 hours of incubation of cells with RhB-SPIONs. All experiments were performed 
on two types of cell lines (MCF7 and MDA-MB-231). 
 
IC50 and IC90 evaluation of SPIONs 
 
Viability was determined by MTT assay. Data obtained were used to calculate the IC50 
and IC90 values for each cell line, administered with DOX-n(COOH)-SPIONs and DOX-
Rhodamine B-SPIONs. For all experiments, 3 x 106 cells from each cell line were 
plated into 150 mm tissue culture dishes, 24 h prior to the nano-composite treatment. 
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In order to determine the corresponding IC50 and IC90 values, the cells were separately 
treated with the as-prepared bare, coated and drug-loaded nano-composites for 24, 
48, 72 and 96 h at 37 °C. Plates were washed thrice with PBS and incubated in 10 mL 
of fresh medium for an additional 48 h before the final cell collection. All the cells were 
collected by sedimenting at 2000 x g for 5 min. 
 
 
Statistical analysis 
All statistical analyses were performed using the IBM Statistical Package for Social 
Sciences v. 20 (SPSS-IBM, Chicago, MI, US). All data were expressed as mean ± SD 
and one-way ANOVA was used for statistical analysis. P values < 0.05 were consid-
ered statistically significant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
X-ray diffractometry of magnetic nanoparticles was used to identify the crystal structure 
and estimate the crystallite size of as-prepared nanoparticles (Fig. 3 A-B). The lattice 
constant a was measured to be 8.310 Å, which was compared with the lattice param-
eter for the magnetite of 8.39 Å [12]. As shown in Fig. 3a, the peaks indexed as planes 
(220), (311), (400), (422), (511) and (440) correspond to a cubic unit cell, characteristic 
of a cubic spinel structure [13]. In addition, the strongest reflection from the (311) plane 
is also the characteristic of such phase. Therefore, it is confirmed that the crystalline 
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structure of obtained magnetite nanoparticles is an inverse spinel type oxide, in accord 
with that of standard data (JCPDS 72-2303).  
The crystal structure of Fe3O4 is very similar to that of γ-Fe2O3, and hence it is very 
difficult to distinguish them from each other by XRD. Thus, XPS was used to further 
analyze the composition signals. As shown in Fig. 3b, the XPS wide-scan spectrum of 
the Fe3O4 nanoparticles is dominated by the Fe signal at the binding energy of about 
720 eV and the O signal at the binding energy of about 550 eV. The C1s core-level 
spectrum in Fig. 3b with binding energy at about 280 eV is attributed to the C=O–O 
species of the citrate acid grafted on the nanoparticle surface. 
 
 
FTIR spectra 
The FTIR spectra of Fe3O4 and functionalized RhB-Fe3O4 nanoparticles are shown in 
Fig. 3C. The absorption that is recorded at 1590 cm-1 reveals the presence of the Rho-
damine-B group, which also suggests the successful modification of RhB (Fig. 3C). 
The spectrum for Fe3O4 nanoparticles is shown in Fig. 5b. As shown for RhB-Fe3O4 
(Fig. 3C), the characteristic bands corresponding to Rhodamine group indicates the 
successful proceeding of reaction. It also suggests that the functionalization reaction 
is performed with a high yield [15].   
   
 
Fluorescence spectra of Rhodamine B iron-oxide nanoparticles 
To examine whether the RhB-Fe3O4 nanoparticles are photostable, it was performed 
a photobleaching experiment in which samples were repeatedly illuminated and the 
corresponding fluorescence intensities were measured [16]. It was observed that the 
fluorescence intensity of the RhB-Fe3O4 nanoparticles, during about 48 h illumination, 
remains almost unaltered. However, as a control experiment, 96% decrease in fluo-
rescence intensity was observed due to the photobleaching of free Rhodamine-B (Fig. 
3 D-E). The preserved fluorescent in the RhB-Fe3O4 nanoparticles can be explained 
by the formation of stable reaction.  
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Figure 3. (A) XRD patterns of Fe3O4, (B) XPS wide-scan spectra of the as-synthesized 
Fe3O4 nanoparticles; (C) FTIR of Rhodamine-B (RhB) (a), Fe3O4 (b), RhB-Fe3O4 (c); 
(D) Fluorescence spectra of RhB and (E) RhB-Fe3O4 in PBS in the beginning (a), and 
after 48 hours (b). 
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TEM physicochemical characterization of SPIONs 
The TEM images of the Fe3O4 and RhB-Fe3O4 nanoparticles are shown in Fig. 4. The 
bare Fe3O4 nanoparticles (Fig. 4) appear aggregated, which is probably a conse-
quence of the removal of the dispersing phase during sample preparation [14].    
The TEM image (Fig. 4) of RhB-Fe3O4 shows that the core of Fe3O4 can be observed. 
It is very clear that the nanoparticles have a discrete core/shell structure. Meanwhile, 
the size distribution of the Fe3O4 nanoparticles (Fig. 4) is very narrow over the wide 
range of the TEM grid area, and the RhB-Fe3O4 nanoparticles exhibit considerable 
dispersion. From TEM analysis, the average diameter of the particles was calculated 
to be 15-20 nm, which is consistent with the XRD analysis. 
 
Figure 4. TEM of Fe3O4 (a) and RhB-Fe3O4 (b and c). 
 
 
Dynamic light scattering analysis 
Size distribution of the synthesized n(COOH)-SPIONs was investigated in an aqueous 
solution with the help of dynamic light scattering (DLS) spectrometer. As shown in the 
Table 1 the mean diameter of the n(COOH)-SPIONs was recorded to be about 92.0 
nm and DOX-loaded polycarboxylic-coated SPIONs was 154.4 nm. The size 
distribution of the bare SPIONs was also determined and recorded to be about 30 nm. 
The average hydrodynamic diameter increases with increased amount of doxorubicin 
from 92 nm to 254.7 nm. The mean diameter of the RhB-Fe3O4 nanoparticles was 
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recorded to be about 74.0 nm and DOX-loaded Rhodamine B-coated SPIONs was 
145.7 nm. 
n(COOH)-SPIONs 
Combination SPIONs/Doxorubicin  Average Size (DLS)  Zeta Potential 
50 µg/ml / 0 µM  92 nm  - 45 mV  
50 µg/ml / 0.5 µM  137.2 nm  - 37.4 mV  
50 µg/ml / 1 µM  109.9 nm  - 49.9 mV  
50 µg/ml / 5 µM  154.4 nm  - 34.1 mV  
50 µg/ml / 50 µM  254.7 nm  - 41.7 mV  
 
Rhodamine B-SPIONs 
Combination SPIONs/Doxorubicin  Average Size (DLS)  Zeta Potential 
50 µg/ml / 0 µM  74 nm  - 30 mV  
50 µg/ml / 0.5 µM  103.4 nm  - 25 mV  
50 µg/ml / 1 µM  124.6 nm  - 31.9 mV  
50 µg/ml / 5 µM  145.7 nm  - 25.9 mV  
50 µg/ml / 50 µM  201.6 nm  - 39.3 mV  
 
Table 1. Dynamic light scattering (DLS) spectrometer of DOX-n(COOH)-SPIONs and 
DOX-Rhodamine B-SPIONs 
 
 
Colloidal stability and hydrodynamic behaviour of SPIONs 
The colloidal stability of n(COOH) and RhB-SPIONs was investigated before cell 
viability evaluation. The hydrodynamic size was measured in a narrow range by DLS 
evaluation after 60 days, as shown in Fig. 5. There was no sign of aggregation and 
flocculation or subsidence after 60 days of storage (Fig. 5). 
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Figure 5. Hydrodynamic sizes of n(COOH) and RhB-SPIONs in aqueous solution as a 
function of storage time. 
 
 
 
Internalization of SPIONs into cells 
The results of ICP-MS showed that higher amount of iron (45.8 ± 1.8 pg) was taken up 
in higher SPIONs concentration (100 μg/ml) (concentration-dependent). After identical 
sample preparation in the control, 10.1 ± 0.9 pg iron per cell could be detected. In the 
case of 50, 100 μg/ml of SPIONs, the numbers were 24.9 and 45.8 pg/cell, respectively 
for n(COOH)-SPIONs, and 21.8 and 38.7 pg/cell for RhB-SPIONs (Fig. 6). 
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Figure 6. ICP-MS of different concentrations of n(COOH) and Rhodamine B 
SPIONs. 
 
 
Material toxicity testing of magnetic nanoparticles leach solution  
The values of cell viability revealed no significant difference in MCF-10A cell growth 
compared with that in the control group after n(COOH)-Fe3O4 and Rhodaminie B Fe3O4 
nanoparticle leaching solution (100%, 75%, 50%, and 25%) was added. The relative 
growth rate is shown in Table 2. The results indicate that the 100% leaching solution 
of n(COOH) and RhB Fe3O4 nanoparticles is cytocompatible toward MCF-10A cells. 
Considering the relative growth rate, the eluates solutions of n(COOH)Fe3O4 and RhB-
Fe3O4 nanoparticles showed a cell viability on MCF-10A cells comparable to control.  
  
n(COOH)-Fe3O4 nanoparticles RhB-Fe3O4 nanoparticles 
Groups 
 
OD 
 
Relative 
growth rate 
(%) 
 
Groups 
 
OD 
 
Relative 
growth rate 
(%) 
 
Control 0.289 + 
0.005 
100 Control 0.289 + 
0.005 
100 
25% extract 
liquid 
0,277 + 
0.004 
95.9 25% extract 
liquid 
0.280 + 
0.008 
97.1 
50% extract 
liquid 
0.271 + 
0.006 
93.8 50% extract 
liquid 
0.273 + 
0.005 
94.6 
75% extract 
liquid 
0.261 + 
0.008 
90.6 75% extract 
liquid 
0.266 + 
0.007 
92.1 
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100% 
extract 
liquid 
0.254 + 
0.006 
87.8 100% 
extract 
liquid 
0.257 + 
0.006 
88.9 
 
Table 2. Leaching extract solutions for n(COOH)-Fe3O4 and Rhodamine-B Fe3O4 nanoparticles. 
 
Direct contact cytotoxicity 
The same conditions were verified on MCF-10A cells. For MCF-10A cells the cell 
viability after 24 hours (MTT assay) range between 80% and 88% for n(COOH)-Fe3O4 
and RhB-Fe3O4 (Fig. 7). DMSO (10% v/v) was used like negative control. The cell 
viability after 48 hours (MTT assay) range between 83% and 91% for n(COOH)-Fe3O4 
and RhB-Fe3O4 (Fig. 7). The cell viability after 72 hours (MTT assay) range between 
82% and 92% for n(COOH)-Fe3O4 and RhB-Fe3O4 (Fig. 7). RhB-Fe3O4 and n(COOH)-
Fe3O4 SPIONs did not affect the viability of mammary epithelial cells in all the 
experimental conditions. These data of cell viability showed cytocompatibility and 
stability of the layer of polycarboxylic acid and Rhodamine B comparable to control 
with a selectivity for cancer cells compared to non cancerous cells.    
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Figure 7. Direct contact cytotoxicity evaluation of n(COOH)-SPIONs and RhB SPIONs (50 and 
100 µg/mL) on MCF-10A cells at different time points. *P < 0.05 compared with control sam-
ples. 
 
 
 
Direct cytotoxicity evaluation of SPIONs and DOX-SPIONs on cancer cells  
The cytotoxicity of DOX loaded n(COOH)-SPIONs was compared with free drug DOX 
in the absence and presence of magnetic field, also the probable cytotoxicity of the 
targeted and non-targeted blank nanoparticles was checked. Cell viability assay 
showed that in MCF-7 and MDA-MB-231 cells the cell survival percentage was 
decreased significantly (p<0.05) in targeted nanoparticles group compared to free 
DOX and naked magnetic nanoparticles in most drug concentrations both in absence 
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and presence of magnetic field without toxic effects on normal mammary epithelial 
cells (MCF-10A). These data indicate that DOX-CA-SPIONs and the presence of 
magnetic hyperthermia led to increasing cytotoxic effects of the nanoparticles on 
breast cancer cells. 
A selective efficacy was observed for DOX-SPIONs on breast cancer cells. The results 
demonstrated the potential of the DOX-n(COOH) SPIONs to achieve dual tumor 
targeting by magnetic field-guided in breast cancer cells, and exploit the incredible 
possibilities to kill in a target way the cancer cells.  
Drug-loading efficiency of doxorubicin showed better results for the n(COOH)-SPIONs 
as compared to the bare ones. For hyperthermia treatment, cells were exposed to 
hypertermic conditions for 30 minutes, corresponding to a temperature dosage of 90 
cumulative equivalent minutes, or else cells will be left in the incubator at 37°C. At 24, 
28, 72 h after hyperthermia, cells viability was tested. The in vitro efficacy was also 
tested without hyperthermia treatment. The incubation of MCF-7 and MDA-MB-231 
human breast cancer cells with doxorubicin-loaded and doxorubicin-loaded 
polycarboxylic acid-coated SPIONs, for 24, 48, 72 h, showed significant IC50 and IC90, 
respectively, after 72 h of incubation (Figure 8 and 9). While, 90% and 93% growth 
inhibition were seen in MCF-7 and MDA-MB-231 cells after the 72-h exposure to the 
doxorubicin n(COOH)-SPIONs (p < 0.05), any type of cytotoxic effect was observed 
on control MCF-10A cells (ATCC, mammary epithelial cells) (Figure 10). These data 
indicate that DOX-n(COOH)-SPIONs and the presence of magnetic hyperthermia led 
to increasing cytotoxic effects of the nanoparticles on breast cancer cells like a very 
promising moonshot for cancer therapy. 
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Figure 8. Direct contact cytotoxicity evaluation of n(COOH)-SPIONs (50 µg/mL)  conjugated 
to Doxorubicin (5 µM) (DOX) and with induced magnetic hyperthermia using breast cancer 
cells (MCF-7 cells) at different time points. Data are shown as the mean ± standard error of 
the mean (n = 4). *P < 0.05 compared with control samples. **P < 0.05 compared to control 
samples and DOX 5 µM.  
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Figure 9. Direct contact cytotoxicity evaluation of n(COOH)-SPIONs (50 µg/mL) conjugated to 
Doxorubicin (5 µM) (DOX) and with induced magnetic hyperthermia using breast cancer cells 
(MDA-MB-231 cells) at different time points. Data are shown as the mean ± standard error of 
the mean (n = 4). *P < 0.05 compared with control samples. **P < 0.05 compared to control 
samples and DOX 5 µM.  
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Figure 10. Direct contact cytotoxicity evaluation of RhB-SPIONs (50 µg/mL) conjugated to 
Doxorubicin (5 µM) (DOX) and with induced magnetic hyperthermia using breast cancer cells 
(MCF-7 and MDA-MB-231 cells) at different time points. Data are shown as the mean ± stand-
ard error of the mean (n = 4). *P < 0.05 compared with control samples. **P < 0.05 compared 
to control samples and DOX 5 µM.  
 
 
Apoptosis evaluation 
The results revealed a dose-dependent induction of early or late apoptotic cell death 
in the breast cancer cell lines (Figure 11). Compared to MDA-MB-231 cells, the MCF-
7 cells showed more cell death. MCF-7 cells showed 91% apoptosis after the admin-
istration of DOX-loaded n(COOH)-SPIONs (5 µM; p < 0.05). While, 87.1% apoptosis 
was seen in the MDA-MB-231 cells under same conditions (p < 0.05), which indicates 
that carboxylic acid-functionalized SPIONs could enhance the DOX-induced apoptosis 
in both of the human breast cancer cell lines. For the cell death onset analysis, MCF-
7 and MDA-MB-231 cells were treated separately with DOX, SPIONs, SPIONs MHT 
and DOX-n(COOH)-SPIONs AMF for 24 h of time. Apoptotic cell death was analyzed 
by staining the cells with Annexin-V-FLUOS staining kit and analyzed by flow cytome-
try. The results revealed a dose-dependent induction of early or late apoptotic cell 
death in these two cell lines (Figure 9). Compared to MDA-MB-231 cells, the MCF-7 
cells showed more cell death. MCF-7 cells showed 91% apoptosis after the admin-
istration of DOX-loaded SPIONs (5 µM; p < 0.05). While, 87.1% apoptosis was seen 
in MDA-MB-231 cells under same conditions (p < 0.05), which indicates that hydroxyl-
modified SPIONs could enhance the DOX-induced apoptosis in both of the human 
breast cancer cell lines. 
 
 
 
Figure 11. Doxorubicin (DOX)-loaded CA-SPIONs system induces apoptosis in MCF-7 and 
MDA-MB-231 cells. Both cancer cell lines were treated separately with DOX, SPIONs, CA-
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SPIONs, and DOX-CA-SPIONs for 24 h. Apoptotic cell death was detected by staining the 
cells with Annexin-V/PI kit and analyzed by flow cytometry. 
Intracellular internalization of Rhodamine-B SPIONs 
The Rhodamine-B conjugated iron-oxide nanoparticles were internalized by both 
MCF-7 and MDA-MB-231 cells as detected by fluorescence microscopy (Figure 10). 
The image in Figure 12 represents the intracellular uptake of nanoparticles bound to 
doxorubicin to kill more specifically breast cancer cells. The co-localization of these 
cells involves the bases of long-time studies and successful internalization  
 
Figure 12. Intracellular Rhodamine B-conjugated iron-oxide nanoparticle (SPIONs) location 
by fluorescence microscopy. 
Notes: Images of different components of MCF7 and MDA-MB-231 cells exposed to DOX-CA-
SPIONs over 24 hours. The color-coded images on the left represent the overlapping of 
cytoplasm (green), nuclei (blue), and DOX-CA-SPIONs (red). 
 
TEM characterization of SPIONs uptake 
The effects of SPIONs and SPIONs-DOX on MCF-7 cells were analysed, as well as 
on their proliferation, by the MTT assay, which were measured in terms of relative 
viability. Conjugated iron-oxide nanoparticles were sparsely scattered throughout the 
cytoplasm and mostly accumulated in membrane structures.  
Following 24 hours of incubation with nanoparticles, it’s possible to observe the 
internalization of particles in the cytoplasm of MCF-7 cells (Figure 13). SPIONs mostly 
accumulated in the cytoplasm in the endosome-like structures surrounding the nucleus. 
When the cells were analyzed by TEM, we could observe the presence of SPION-DOX 
conjugates included as electron-dense particles in membrane structures within the 
cytoplasm (Figure 14a). Transmission electron microscopy to characterize the 
subcellular localization demonstrated that SPIONs complexes were colocalized in 
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endosomes (Figure 14b and c). This proposes a mechanism of receptor-mediated 
endocytosis of SPIONs-DOX conjugates by MCF-7 cells. 
 
 
Figure 13. Transmission electron microscopy of the MCF-7 cells incubated with SPIONs. 
Notes: Following incubation with SPIONs (150 μg/mL) for 24 hours, nanoparticles could be 
detected as being attached to the cell membrane (blue arrows) and incorporated into the 
endosome-like structures in the cytoplasm (red arrows). Scale bar: 2 μm. 
 
 
Figure 14. TEM of MCF-7 cells incubated for 24 hours with SPION-DOX conjugates.  
Notes: (a) TEM of MCF-7 cells incubated for 24 hours with bare iron-oxide nanoparticles. 
Electron-dense nanoparticles were present in the cytoplasm of cells in endosome-like 
structures (red solid arrow). Scale bar: 500 nm. (b), (c) TEM of cells incubated with SPIONs-
DOX conjugates for 24 hours.  
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In vitro toxicity of doxorubicin loading onto the SPIONs 
IC50 and IC90 analyses of MCF-7 and MDA-MB-231 cell lines, after 24, 48, 72, 96 h 
exposure to DOX-loaded polycarboxylic-coated SPIONs were recorded at 1.9 ± 0.5 
and 4.2 ± 0.7 mM concentration of drug, while, IC90 of both cell lines was seen at 4.3 
± 0.7 and 6.8 ± 1.0 mM DOX concentration after 96 h for MCF-7 and MDA-MB-231 
cells respectively. Inhibition concentrations for DOX-loaded Rhodamine B-SPIONs 
were recorded at 2.0 ± 0.6 and 3.9 ± 0.8 mM concentration of drug for IC50, while, IC90 
of both cell lines was seen at 4.0 ± 0.8 and 6.0 ± 1.2 mM DOX concentration after 96 
h for MCF-7 and MDA-MB-231 cells respectively. This demonstrates that the MDA-
MB-231 cells were more resistant to the lower concentrations of drug as compared to 
the MCF-7 cells (Table 3; p < 0.05).    
 
Table 3: IC50 and IC90 of MCF-7 and MDA-MB-231 cell lines after 24, 48, 72, 96 exposure to 
DOX-loaded n(COOH)-SPIONs 
 24 h 48 h 72 h 96 h 
 IC50 for DOX-loaded n(COOH)-SPIONs (mM) 
Type of cell line     
MCF-7 4.0 ± 0.9 3.1 ± 0.8 2.4 ± 0.7 1.9 ± 0.5 
MDA-MB-231 6.4 ± 1.8 5.3 ± 1.2 4.8 ± 0.9 4.2 ± 0.7 
     
 IC90 for DOX-loaded n(COOH)-SPIONs (mM) 
Type of cell line     
MCF-7 8.9 ± 1.5 7.6 ± 1.0 6.1 ± 0.6 4.3 ± 0.7 
MDA-MB-231 10.6 ± 3.4 9.4 ± 2.1 7.3 ± 0.8 6.8 ± 1.0 
 
Table 4: IC50 and IC90 of MCF-7 and MDA-MB-231 cell lines after 24, 48, 72, 96 exposure to 
DOX-loaded Rhodamine B-SPIONs 
 24 h 48 h 72 h 96 h 
 IC50 for DOX-loaded Rhodamine B-SPIONs (mM) 
Type of cell line     
MCF-7 3.8 ± 0.9 3.0 ± 0.7 2.3 ± 0.6 2.0 ± 0.6 
MDA-MB-231 6.7 ± 1.4 5.6 ± 1.0 4.6 ± 0.8 3.9 ± 0.8 
     
 IC90 for DOX-loaded Rhodamine B-SPIONs (mM) 
Type of cell line     
MCF-7 8.7 ± 1.3 7.4 ± 1.1 5.9 ± 0.7 4.0 ± 0.8 
MDA-MB-231 10.9 ± 2.7 9.6 ± 2.0 7.7 ± 1.3 6.0 ± 1.2 
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DOX, doxorubicin. The IC50 and IC90 are defined as the concentrations causing 50% and 90% 
growth inhibition in treated cells, respectively, when compared to control cells. Values are 
means ± SEM of at least three separate experiments. 
 
DOX release profile 
The DOX release profiles of n(COOH)-SPIONs and Rhodamine B-SPIONs were 
analyzed to check the free and the conjugated drug, at the pH range of 1.5-7.0. At Ph 
7.0, a small amount of the drug release was observed after the incubation period of 48 
h. 
The DOX release profiles of the free and the conjugated drug, at the pH range of 1.5-
7.0. At pH 7.0, a small amount of the drug release was observed after the incubation 
period of 48 h. This is a desirable characteristic as the pH 7.4 is the undesired pH for 
the proper release of the drugs from the nanoconjugated drug carrier. This will also 
prevent the premature release of the drugs before the nanoconjugates reach the 
cancer cells. It shows that the pH 6.0 provided the desirable conditions for the proper 
drug release. The first 10 h represent the period of initial rapid release, followed by a 
steady state.  
This pH-dependent drug release behavior is favorable for the chemotherapeutic 
process as it can significantly reduce the preterm drug release on the body pH level 
(pH 7.4) and maximizing the amount of drug reaching the target tumor cells, once the 
drug-loaded SPIONs internalize and enter the tumor by endocytosis (pH 4.5-6.5) 
(Figure 15). 
 
Figure 15. DOX release profiles of the free and the conjugated drug. 
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Discussion 
The aim of the study was to couple a second generation of superparamagnetic 
nanoparticles with doxorubicin, a very effective chemotherapeutic agent used for 
breast cancer therapy. Due to the well-known toxicity of Doxorubicin, new ways to 
deliver the drug into target tissues are urgently needed.  
The magnetic core of the nanoparticles was designed to induce controlled magnetic 
hyperthermia by an external magnetic field. Superparamagnetic iron oxide MNPs were 
successfully synthesized by co-precipitation method that is facile and versatile ease of 
synthesizing. The great advantage of this synthesis method is high yield in the 
production of nanoparticles in a short time.  
The pursuit of innovative, multifunctional, more efficient, and safer treatments is a 
major challenge in preclinical nanoparticle-mediated thermotherapeutic research for 
breast cancer. Here, we reported that iron oxide nanoparticles have the dual capacity 
to act as both magnetic and drug delivery agents.  
Doxorubicin-loaded polycarboxylic acid-coated superparamagnetic iron oxide nano-
particles (Fe3O4; n(COOH)-SPIONs) with an average particle size of 30 nm, with high 
encapsulation efficiencies, were obtained by the electrostatic loading of doxorubicin 
(DOX) to SPIONs through the electrostatic interaction between the carboxyl group of 
carboxylic acid functionalized iron-oxide nanoparticles and the amine group of DOX. 
Iron oxide-based magnetic nanoassemblies are a family of drug delivery systems with 
high potential like theranostic due to their low toxicity, size-dependent superparamag-
netism, large surface area, and biocompatibility. In this study, we tested a novel DOX 
nanocarrier and its effects on normal and breast cancer cell lines.  
In order to verify the targeting efficacy of nanoparticles, cell viability evaluation was 
conducted to estimate the viability of MCF-7 and MDA-MB-231 cells related to the in 
vitro efficacy of DOX, DOX-SPIONs, and DOX-SPIONs MHT with DOX concentration 
of 5 µM for 24, 48 and 72 hours. A gradually time-dependent decreasing trend in the 
cell viability with all treatments was observed. We found that the cell viability of DOX-
SPIONs-treated cells was lower than that of only DOX-treated cells, and the difference 
was statistically significant; this may be explained by the action of DOX-SPIONs con-
jugates which can be easily translocated across the plasma membrane by endocytosis 
into breast cancer cells to exert their inhibitory effect on the cells. The viability of the 
DOX-SPIONs-treated cells was lower than that of the other two groups (p<0.05). The 
active targeting of conjugated nanoparticles led to more successful transport through 
the cellular membrane. The half inhibitory concentration of DOX-SPIONs at 24 hours 
was ~4.0 and ~6.4 mM for MCF-7 and MDA-MB-231 cells, respectively. Additionally, 
DOX released from the DOX-SPIONs was measured through dialysis at range of pH 
between 1.5 and 7.0 (Figure 3). Under conditions including a neutral dialysate (pH 
=7.4), DOX-SPIONs displayed a slow and sustained DOX release rate of ~50% within 
7 hours, with ~90% of DOX released within 14 hours. These results show that DOX-
SPIONs ensure a smooth and continuous diffusion of DOX in a neutral environment. 
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The comparison of the results of this study according to literature showed a promising 
ability of doxorubicin-conjugated iron-oxide nanoparticles to promote targeted 
apoptosis of cancer cells and a potential to act as an antimetastatic 
chemothermotherapeutic agent [11]. 
This work aimed to implement an innovative multi-therapeutic strategy that combines 
the use of superparamagnetic iron oxide nanoparticles properties for dual tumor tar-
geting therapy on cancer cells by exploiting magnetic induced hyperthermia and se-
lective drug delivery to target cancer. One factor that can contribute to nanotoxicity is 
the size of the particles. Smaller particles have a greater reactive surface area, are 
more chemically reactive, and produce higher numbers of ROS than larger particles. 
This is one of the primary mechanisms of nanotoxicity and it may result in the oxidative 
stress causing inflammation and damage to proteins, membranes, and DNA. The size 
and surface charge of NPs are important physiochemical parameters in designing drug 
delivery vehicles for therapeutic applications. Transition metal ions such as Fe(II) and 
Fe(III) can generate ROS. Superoxide, produced via normal metabolic processes and 
redox cycling within the cell, reacts with hydrogen peroxide to form hydroxyl free radi-
cals. The catalysts in the present case are the iron ions on the surface of SPIONs. 
Free radicals generated by SPIONs or DOX-SPIONs are responsible for oxidative 
stress and cell damage (lipid peroxidation and protein oxidation). 
The major mechanism of action of free DOX involves its intercalation in the DNA and 
inhibition of topoisomerase II. Several secondary mechanisms of DOX action are 
described as DOX-induced production of ROS. Mitochondrially located ROS can also 
be detected rapidly after DOX administration, most probably due to respiratory chain-
produced superoxide radicals. One feature of DOX is to produce ROS via one-electron 
reduction to the corresponding semiquinone free radicals that then react rapidly with 
oxygen to generate superoxide radical anions. 
In our research, DOX-SPIONs showed greater targeted cytotoxicity than free DOX on 
breast cancer cells, regardless of DOX concentration. Viability was decreased with 
increasing DOX concentration. High cytotoxicity is based on successful delivery of 
DOX into the nuclei of cancer cells. The treatment with DOX alone produced a very 
substantial decrease in cell viability. The incorporation of DOX into SPIONs core 
strongly enhanced the cytotoxic effect of drug when compared with the free drug. 
The aim of this study was to investigate the application of SPIONs in magnetic hyper-
thermia of MCF7 cancer cells. 
The results demonstrated the potential of the DOX-n(COOH)-SPIONs and RhB-
SPIONs to achieve dual tumor targeting and magnetic-induced drug delivery by 
magnetic field-guided in breast cancer cells. This may reduce the required dose of 
doxorubicin and consequently reduction the side effects of this drug. We discovered 
an intrinsic therapeutic effect of magnetic nanoparticles on cancer growth of breast 
cancer cells. We produced a novel innovative nanoparticle with multifunctional feature 
for magnetic targeted tumor diagnosis and anticancer therapy. The nanoplatform 
produced exhibits the high magnetization, excellent stability as well as high efficiency 
of targeted drug delivery. Tumor targeting can be obtained under the guidance of an 
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external magnetic field, which improves the specific delivery of nanoparticles to the 
tumor sites and thus improve the therapeutic efficacy greatly. So, we have 
demonstrated that DOX-SPIONs can promote apoptosis and lessen the negative 
effects of chemotherapeutic agents on control cells mammary epithelial cells during 
the in vitro conditions because they have a targeted cytotoxic effect on cancer cell 
lines. To optimize this drug delivery system, greater understanding of the different 
mechanisms of biological interactions, and particle engineering, is still required. 
Further advances are needed in order to turn the concept of nanoparticle technology 
into a realistic practical application as the next generation of drug delivery system. 
 
 
Conclusion 
 
In this study, polycarboxylic and Rhodamine-B iron-oxide nanoparticles were 
successfully synthesized. Our current study indicated the clear advantages of DOX-
SPIONs in comparison with free DOX or bare n(COOH)-SPIONs for the treatment of 
breast carcinoma without discernible side effects. Furthermore, the established and 
relevant MRI technology could be readily used to orientate DOX-SPIONs for preferable 
diagnosis and treatment of breast cancer. DOX-SPIONs equipped with dual targeting 
methods and targeted drug delivery capacity are a promising theranostic candidate for 
breast cancer. According to these results, the prepared nanoparticles are efficient and 
appropriate theranostics tools for breast cancer cells. 
In conclusion, this study indicates that SPIONs are promising therapeutic agents for 
magnetic hyperthermia of breast cancer cells and offers a dual magnetotherapeutic 
approach with iron oxide nanoparticles as the sole heat mediators. We demonstrated 
that iron oxide nanoparticles can be remotely activated with an alternating magnetic 
field, achieving a very efficient heat conversion. Remarkably, the dual magnetic and 
drug delivery action resulted in complete cell death in vitro at low iron doses, tolerable 
magnetic field and frequency conditions. This cumulative, if not synergistic, heat 
therapy is thus promising for tumor treatment with minimal collateral tissue damage. 
DOX-SPIONs for targeted cancer chemotherapy are exocytosed from tumor cells after 
incubation. In summary, we have successfully developed biocompatible magnetic 
nanoparticles platform for targeted cancer chemotherapy. Our study clearly 
demonstrates that iron-oxide nanoparticles have potential as drug carriers to improve 
the anticancer efficacy.    
 
Future directions 
The therapeutic approaches based on enhanced permeability and retention (EPR) 
effect can sustain an increased nanoparticles-based drug delivery system for cancer 
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therapy. The external field triggered nanotheranostics (therapy + diagnostics) 
approach together with can allow precise control of the drug release, timing, intensity, 
duration of drug delivery and treatment monitoring. This means a boost to the treatment 
all-in-one efficacy. 
This can be observed like a progression for convergence therapy with real-time 
monitoring of tumor destruction. When tumor cells are incubated with doxorubicin-
loaded magnetic nanoparticles the tumor cells can retain for longer time the 
nanoparticles. DOX-SPIONs could exhibit enhanced tumor accumulation, tumor 
penetration and cross-reactive cellular uptake, resulting in augmented DOX 
enrichment in total tumor cells and side population cells.  
Several physical energy sources could be used in future to trigger hybrid 
nanostructures. In recent times various research groups have invented novel ways to 
utilize nanoscale materials that are capable of responding to external physical stimulus 
such as (i) light (ii) magnetic fields (iii) ultrasound (iv) radiofrequencies (v) x-rays. Novel 
nanostructures are highly sensitive to external stimulus and can perform ‘on demand’ 
cancer theranostics. 
The perspective use of iron-oxide nanoparticles in nanotheranostics application can 
be a perspective use and application for targeted use of medical physics solutions to 
contrast cancer advancement. 
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